Compare YMAT & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMAT | MBIO |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.1M |
| IPO Year | 2021 | 2023 |
| Metric | YMAT | MBIO |
|---|---|---|
| Price | $1.01 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 31.4K |
| Earning Date | 10-23-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $405.45 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.35 |
| 52 Week High | $4.49 | $1.44 |
| Indicator | YMAT | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 42.60 |
| Support Level | $0.32 | $0.35 |
| Resistance Level | $2.20 | $0.43 |
| Average True Range (ATR) | 0.26 | 0.03 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 26.53 | 7.63 |
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.